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Treatment-inducedCurrently, 17–19% of all new primary malignancies occur in survivors of cancer, causing
substantial morbidity and mortality. Research has shown that cancer treatments are
important contributors to second malignant neoplasm (SMN) risk.
In this paper we summarise current knowledge with regard to treatment-related SMNs and
provide recommendations for future research. We address the risks associated with radio-
therapy and systemic treatments, modifying factors of treatment-related risks (genetic
susceptibility, lifestyle) and the potential benefits of screening and interventions. Research
priorities were identified during a workshop at the 2014 Cancer Survivorship Summit
organised by the European Organisation for Research and Treatment of Cancer.
Recently, both systemic cancer treatments and radiotherapy approaches have evolved rap-
idly, with the carcinogenic potential of new treatments being unknown. Also, little knowl-
edge is available about modifying factors of treatment-associated risk, such as genetic
variants and lifestyle. Therefore, large prospective studies with biobanking, high quality
treatment data (radiation dose–volume, cumulative drug doses), and data on other cancer
risk factors are needed. International collaboration will be essential to have adequate
statistical power for such investigations. While screening for SMNs is included in several
follow-up guidelines for cancer survivors, its effectiveness in this special population has
not been demonstrated. Research into the pathogenesis, tumour characteristics and
survival of SMNs is essential, as well as the development of interventions to reduce
SMN-related morbidity and mortality. Prediction models for SMN risk are needed to inform
initial treatment decisions, balancing chances of cure and SMNs and to identify high-risk
subgroups of survivors eligible for screening.
 2014 European Organisation for Research and Treatment of Cancer. Published by Elsevier
Limited. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).sterdam,
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Currently, 17–19% of all new primary malignancies occur in
individuals who have already survived a primary malignancy
[1,2]. In the Netherlands, the proportion of second and subse-
quent malignancies (including second cancers in paired
organs) increased from 10% in 1989 to 17% in 2013 [1]. In the
U.S. National Cancer Institute’s (NCI) Surveillance, Epidemiol-
ogy and End Results (SEER) Programme, the proportion of can-
cers that are second and subsequent malignancies has more
than doubled in the last three decades, from 9% in 1975–
1979 to 19% in 2005–2009 [2].
Research conducted over the last three decades has clearly
demonstrated that, paradoxically, some treatments used suc-
cessfully to treat cancer have the potential to induce new
(second) primary malignancies. Increased risks of second
malignant neoplasms (SMNs) have been observed after radio-
therapy, certain chemotherapy regimens and hormonal treat-
ments. Of all late complications of treatment, SMNs are
among the most serious because they cause not only substan-
tial morbidity but also considerable mortality. For example,
death due to SMNs is the largest contributor to long-term
excess mortality among survivors of Hodgkin lymphoma
(HL) [3,4].
Despite the importance of treatment-related SMNs, it
must be recognised that SMNs may also be due to other
causes. Aside from treatment the occurrence of two primary
malignancies in the same individual may result from host
susceptibility factors (e.g. genetic predisposition or immuno-
deficiency), carcinogenic influences in common, or indeed
several of these factors may come into play [5–7]. Alterna-
tively, the primary malignancies may be unrelated, and their
occurrence in a single individual may arise by chance alone.
In view of the high prevalence of cancer in the general popu-
lation and the increasing incidence of most cancers with
older age, background aetiological factors other than treat-
ment are likely to be responsible for a substantial proportion
of SMNs. Therefore, to properly evaluate the risk of SMN,
comparison with cancer risk in the general population is
important.
In this paper we summarise current knowledge regarding
treatment-related SMNs, identify gaps in knowledge and pro-
vide recommendations for future research. In particular, we
will address the risks associated with radiotherapy, systemic
treatments including chemotherapy and hormonal agents
and potential synergistic effects of different treatments. We
will also describe the key factors that may modify the treat-
ment-related SMN risks, including age, genetic susceptibility
and other cancer risk factors such as cigarette smoking.
Finally, we will discuss the potential benefits of screening
and other interventions aimed at reducing SMN risk. The cur-
rent perspective represents a summary of discussions during
a workshop at the 1st Cancer Survivorship Summit organised
by the European Organisation for Research and Treatment of
Cancer (EORTC), which was held on January 30, 2014 in Brus-
sels, Belgium. The EORTC Survivorship Summit focused on
survivorship issues after malignancies occurring in adoles-
cence and adulthood.2. Radiotherapy
Extensive understanding of the cancer risks following ionis-
ing radiation exposure derives from studies of patients
exposed to diagnostic or therapeutic irradiation, victims of
nuclear accidents and survivors of the atomic bombings in
Japan [8–11]. Particularly high risks following radiation expo-
sure are evident for cancers of the brain, thyroid, female
breast, skin (basal cell carcinoma), bone and soft tissue. Mod-
estly increased risks also are reported for cancers of the lung,
gastrointestinal tract and bladder, as well as myeloid
leukaemias.
For most tissues, cancer risks increase linearly with
increasing radiation dose, though the magnitude of the risk
differs substantially. For example, the excess relative risk
per Gy is 0.09 (95% confidence interval [CI] 0.04–0.21) for stom-
ach cancer, 0.15 (0.06–0.39) for lung cancer and 0.15 (0.04–0.73)
for breast cancer after HL [12–14], and 0.33 (0.01–1.71) for gli-
oma, 1.06 (0.21–8.15) for meningioma and 1.32 (0.44–4.22) for
sarcoma after childhood cancer [15,16]. In contrast, for thy-
roid cancer, risk increases linearly until approximately 20 Gy
and declines thereafter, consistent with a model in which
higher radiation doses kill rather than transform cells [17],
and for leukaemia, some studies suggest a similar pattern,
though with a decline at approximately 4 rather than 20 Gy
[18]. However, the magnitude and shape of the radiation
dose–response relation remain unknown for certain cancer
types, such as colon and pancreatic cancers, particularly for
the radiation doses experienced by patients undergoing
radiotherapy.
In addition to the type of tissue exposed and the radiation
dose, the time period over which the exposure occurs and the
time since exposure are key determinants of radiation-related
cancer risk. For example, patients undergoing radiotherapy,
who generally receive fractionated exposures of 1–5 Gy per
fraction and cumulative doses of 15–>50 Gy, have lower risks
per unit dose than atomic bomb survivors, who received a
single acute exposure primarily <2 Gy [19]. Finally, the time
since exposure is an important determinant of subsequent
cancer risk, with most radiation-related cancers not appear-
ing for at least a decade following exposure, and increased
risks persisting for decades thereafter [8–11,20,21].
Radiotherapy treatments have evolved substantially in
recent decades, with certain patients treated with lower
doses, smaller field sizes and novel techniques such as inten-
sity-modulated radiation therapy (IMRT) and proton therapy
[22]. Because radiation-related cancer risks often are not
observed for at least a decade after exposure, the extent to
which these changes will modify SMN risk is uncertain
[23,24]. Although these contemporary treatments generally
reduce the amount of normal tissue exposed to high radiation
doses (>10 Gy), in some circumstances they can increase the
amount exposed to lower doses (1–9 Gy). Thus, a better under-
standing of the dose-risk relationship across a range of nor-
mal tissue doses is needed to understand the SMN risks
following contemporary radiotherapy. Currently, despite the
ability of modern radiotherapy planning systems to quantify
individuals’ normal tissue doses in detail, there is almost no
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ment plans to minimise SMN risks without compromising ini-
tial cure, or to provide individual-level counselling about
risks.
Additionally, future studies should account for the volume
of tissue exposed at each dose level, particularly because lar-
ger radiation volumes have been shown to increase risk of
SMNs [25]. Documentation of normal tissue doses for patients
undergoing radiotherapy should also become a standard part
of modern clinical practice. Finally, with the expanded use of
proton therapy in the last decade, further research is needed
to improve understanding of the biologic effects and SMN
risks associated with proton (and neutron) exposures com-
pared with photon exposures.
3. Systemic treatments
Some systemic anti-cancer therapies, including chemothera-
peutic agents, hormone therapy and possibly immunomodu-
lators, have been associated with increased risk of developing
SMNs. The most well established association is for myeloid
neoplasms, primarily therapy-related acute myeloid leukae-
mia (t-AML) and myelodysplastic syndrome (t-MDS) [26]. Rel-
ative risks (RRs) for t-AML/t-MDS tend to be very high (10–100-
fold increased) but the absolute excess number of cases is
rather low due to the low background risk [27,28]. Chemother-
apies with well-known leukaemogenic potential include
alkylating agents, topoisomerase II inhibitors and antimetab-
olites [7,26]. Dose-dependent risk of t-AML/t-MDS has been
reported after almost all alkylating agents, such as mechlor-
ethamine, cyclophosphamide, procarbazine, melphalan,
busulfan and cisplatin [29–32], as well as topoisomerase II
inhibitors [33–37]. However, the leukaemogenicity of different
agents varies substantially. For example, melphalan is 10
times more leukaemogenic than cyclophosphamide [38],
and RRs associated with mitoxantrone are five times higher
than those for anthracyclines [35]. T-AML after alkylating
agent exposure typically arises after a latency period of
5–8 years, is frequently preceded by myelodysplastic syn-
drome (MDS), and often has a complex karyotype with
chromosome 5/7 abnormalities [39,40]. In contrast, t-AML
after topoisomerase II inhibitors typically arises in <3 years,
is rarely preceded by MDS, and is characterised by 11q23 or
15/17 aberrations [41]. Evidence increasingly suggests that
chemotherapy also may play a role in the development of
non-haematologic SMNs, which typically occur >10 years
after exposure [7]. Alkylating agents have been reported to
increase risks for lung, thyroid, gastrointestinal and bladder
cancers as well as sarcoma. For example, lung cancer risk
after HL is increased 2–>4-fold with increasing number of
cycles of alkylating agent-containing chemotherapy,
particularly mustine, vincristine, procarbazine, prednisolone
(MOPP) [42–46]. Among childhood cancer survivors, receipt
of any alkylating agent has been associated with 2.4-fold
increased risk for thyroid cancer; receipt of procarbazine
and platinum has been associated with 3.2- and 8.6-fold
increased risk, respectively, of gastrointestinal cancer, and
both alkylating agents and anthracyclines have been associ-
ated with sarcoma risk [16,47–49]. The causal link betweencyclophosphamide and bladder cancer represents one of the
few established relationships between a specific alkylating
agent and carcinogenesis at a specific site, likely as a result
of direct genotoxic exposure of bladder epithelium from
cyclophosphamide metabolites [50,51]. Procarbazine-related
risks for the gastrointestinal tract also may be related to
direct exposure [12,16,52,53], whereas the mechanisms of car-
cinogenesis for agents administered intravenously and for
other malignancies (e.g. lung) are unknown.
With increasing use of systemic therapy and rapid
introduction of new drugs into the clinic, further research
into potential risks of SMNs following systemic therapy is
needed. Large sample sizes, long-term follow-up and a
diverse patient population will be particularly important
because the frequent use of combined modality therapy and
multidrug regimens renders it difficult to disentangle the
effects of specific agents. Examples are the introduction of
new drugs such as taxanes, lenalidomide and monoclonal
antibodies (e.g. rituximab); the use of more intensified regi-
mens, growth factor support and targeted therapy (e.g. tyro-
sine kinase inhibitors); and increasing frequency of
successful treatment for relapse, often resulting in larger
cumulative doses. The importance of pursuing such research
is emphasised by preliminary reports of SMN risks. Data on
the role of taxanes in the development of t-AML are conflict-
ing [54–58], partly due to their use in combination with vari-
ous cytotoxic agents and in different intensity. In addition,
taxane-containing regimens also frequently use granulo-
cyte-colony stimulating factor (G-CSF), whose leukaemogenic
potential continues to be debated [54,58,59]. Lenalidomide, an
immunomodulator used in multiple myeloma treatment,
may increase t-AML risk [60]. For rituximab-containing regi-
mens (often used in non-Hodgkin lymphoma), there is also
suggestive evidence for an association with acute myeloid
leukaemia (AML) [61,62], but generally studies investigating
the risk of SMNs with the wider use of monoclonal antibodies
are lacking [63]. Finally, in terms of SMN risks and hormonal
treatments, tamoxifen has been associated with two- to five
fold duration-dependent increased risk of endometrial cancer
[64–66]. However, long-term effects of aromatase inhibitors,
which are increasingly used with or without tamoxifen, are
not known.
4. Interactions between treatments
Evaluation of the carcinogenic effects of therapy is often com-
plicated by the fact that therapeutic agents are frequently
given in combination. SMN risk after combined modality
treatment (radiotherapy and systemic therapy combined)
may differ from the summed risks seen after either treatment
type alone – with larger risks after combined modality treat-
ment implying synergistic effects of different treatments,
and smaller risks implying antagonistic effects.
Although of great interest, few high quality studies with
sufficient sample size to evaluate potential treatment interac-
tions have been conducted. A recently published interna-
tional study on stomach cancer risk after HL treatment
provided the first robust evidence for the possibility of supra-
multiplicative interaction between exposure to alkylating
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[12]. Radiation doses to the stomach ofP25 Gy combined with
exposure to high-dose procarbazine (P5600 mg/m2) were
associated with an odds ratio (OR) of 77.5 (95% CI, 14.7–
1452), compared to ORs of 2.8 and 1.2 for exposure to
P25 Gy of radiation alone and exposure to high-dose procar-
bazine (P5600 mg/m2) alone, respectively (Fig. 2).
In contrast with this report on stomach cancer risk, two
studies have reported no apparent synergism between che-
motherapy and radiotherapy on subsequent lung cancer
risk [42,43]. Although the OR for lung cancer was 5.9 (95%
CI 2.7–13.5) after >5 Gy to the lung without chemotherapy
and 4.2 (95% CI, 2.1–8.8) after alkylating agents alone, the
estimated RR of 8.0 (95% CI, 3.6–18.5) for patients who
received both treatments did not deviate from the risk
expected if the risks for the individual treatments were
summed [42].
Results are inconsistent regarding the role of combined
modality treatment and risk of subsequent leukaemia. How-
ever, in the largest case–control study to date, among HL
patients with a given dose of alkylating chemotherapy, risk
of leukaemia did not consistently increase with higher radia-
tion dose while leukaemia risk clearly increased with increas-
ing dose of alkylating agents within categories of radiation
dose [67]. However even in the lowest dose category in this
study (<10 Gy) many patients may have been exposed to
myeloablative doses already and it may be that synergy
between radiation and alkylating chemotherapy is only pres-
ent in the lower dose range (<2–4 Gy).
The strongly reduced breast cancer risk among female
childhood cancer and HL patients treated with chest irradia-
tion and alkylating agent-containing chemotherapy com-
pared to patients treated solely with chest irradiation may
provide an example of antagonism between treatment
modalities [13,25,68–71]. In a large British HL cohort breast
cancer risk was 4.6-fold increased compared to the female
general population among those treated with combined
modalities and 14.4-fold after radiotherapy alone, while no
breast cancers occurred among women treated solely with
chemotherapy [68]. Breast cancer risk in patients treated
with chest irradiation was also reduced in those patients
who additionally had received pelvic radiation, suggesting
that premature ovarian failure is a driving force behind this
risk reduction [13,69,71]. Another example of a possible
antagonistic relation between treatments is the risk of thy-
roid cancer after childhood cancer. In a long-term follow-
up study of childhood cancer survivors, chemotherapy-
related risks were only evident among children who did
not receive radiation (OR = 4.6, 95% CI .8–86.3) or who
received <20 Gy to the thyroid (OR = 4.0, 95% CI 1.4–16.5),
but not for children who received P20 Gy to the thyroid
(OR = 1.1, 95% CI 0.6–2.1) [72].
Because of the increasing use of combined modality ther-
apy, additional large studies with high quality treatment data,
including dosimetry data (dose–volume information) and
cumulative doses of systemic therapy, are needed to obtain
sufficient power to investigate potential interactions between
radiation and chemotherapy as well as between various
chemotherapy agents. Furthermore, additional research isneeded to elucidate the mechanisms by which treatments
may interact.
5. Modification of treatment-related second
cancer risks by age
Numerous studies support the importance of age at initial
treatment and age at SMN occurrence (i.e. attained age) as
modifiers of treatment-related SMN risks. Generally, but not
always, the relative risk (RR) of developing a SMN compared
with the general population is higher at younger versus older
ages, whereas the pattern of excess absolute risk (EAR) across
different ages vary by type of both first and second cancer
(Fig. 1) [20,21,25,27,73]. For example, a study of breast cancer
after HL revealed that as the age at HL diagnosis increased
from 620 to 41–50 years, the RR declined from 17.9 to 1.4
and the EAR declined from 79 to 11 cases per 10,000 persons
per year [25]. However, another study suggested that as the
age at breast cancer occurrence (i.e. attained age) increased,
the RR also declined but the EAR increased [20]. In contrast,
the risk (RR and EAR) for thyroid cancer after HL did not vary
by attained age [20]. Because most cancer rates in the general
population increase substantially with increasing age, even
steady or declining RRs with increasing age can be associated
with strikingly increasing EARs, such as the pattern described
above for breast cancer after HL [20].
The key factors that contribute to differences in SMN risks
by age include the baseline cancer rate in the general popula-
tion, potential differences in tissue susceptibility to radiation
or chemotherapy exposure at different ages and the roles of
other cancer risk factors. More research is needed to under-
stand the independent and joint effects of age at exposure
and attained age, particularly expanding beyond the research
in survivors of HL to include survivors of other primary malig-
nancies. Additionally, much of the research to date has
focused on age-related effects of radiotherapy exposures. For
example, childhood cancer survivors receiving cranial irradia-
tion before age 5 years reportedly have significantly higher
risk of subsequent glioma than children irradiated at age P5
[15]. Similarly, thyroid cancer risk is higher among children
irradiated before age 10 years [17]. These particularly elevated
risks at younger ages have been attributed to radiosensitivity
of developing tissues. For second primary breast cancer, the
data on the role of age at exposure are conflicting. Although
some studies have suggested that risks are the highest for girls
receiving chest-directed radiotherapy during puberty, with
lower risks both pre- and post-puberty, additional research
with sufficient numbers of individuals exposed at a wide
range of ages is needed [13,70,74,75]. Much less is known about
potential age-related effects of chemotherapy exposures.
With the expansion of research into non-treatment risk
factors for SMNs, the role of lifestyle and medical history fac-
tors in SMN aetiology is increasingly recognised. Because
these exposures accumulate as ias individuals age, (Must be
plural you can also say : As people age) age, they may play a
greater role in SMNs occurring among older cancer survivors
[76]. Further research will be needed to understand whether
potential interactions between treatment and other cancer
risk factors may depend on age.
Fig. 2 – Risk of stomach cancer after Hodgkin lymphoma in relation to radiation dose to stomach and procarbazine dose. OR,
odds ratio. (*) Radiation dose was estimated to stomach tumour location (matched location for controls). () Assuming
procarbazine dose of 1400 mg/m2 per cycle (14 days · 100 mg/m2 per day), categories correspond to zero, one to three, four to
five, and Psix cycles of MOPP (mechlorethamine, vincristine, procarbazine and prednisone) or MOPP-like regimens. Other
protocols (e.g. MOPP-ABV [MOPP–doxorubicin, bleomycin and vinblastine], BEACOPP [bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine and prednisone]) include procarbazine dose of 700 mg/m2 per cycle. () ORs and
95% confidence intervals (CIs) were adjusted for receipt of any dacarbazine and unknown radiation dose. From: Morton et al.
Fig. 1 – Relative risk (RR) and Absolute Excess Risk of supra- and infradiaphragmatic solid cancers according to age at Hodgkin
lymphoma (HL) diagnosis and attained age. Panel A: RR of supra- and infradiaphragmatic solid cancers. Panel B: AER of
supra- and infradiaphragmatic solid cancers. From: Hodgson et al. [20].
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second cancer risks
Although genetic susceptibility to cancer in general is well
established, little is known about genetic susceptibility to
treatment-related SMNs. Individuals with Li–Fraumeni syn-
drome have long been thought to be highly radio-sensitive,
yet no study has had the sample size and detailed treatment
exposure and genetics data to quantify the risks, as exempli-
fied by a recent review of the literature that yielded a total of
23 patients from 10 studies and case reports [77]. Outside of
the context of cancer predisposition syndromes, most studies
have investigated SMN risks in relation to specific genes,selected based on understanding of biologic pathways of drug
metabolism and carcinogenesis. These studies have reported
associations for variants in oxidative stress, DNA detoxifica-
tion and DNA repair genes with treatment-related leukaemia
[78–84], Ataxia Telangiectasia (AT) gene variants and muta-
tions in DNA Damage Repair Pathway (DDRP) genes with con-
tralateral breast cancer [85,86], and FGFR2 with breast cancer
after supradiaphragmatic radiotherapy for HL [85].
More recently, genome-wide association studies (GWAS),
which agnostically interrogate hundreds of thousands-
to-millions of variants across the genome [87], have revealed
genomic regions associated with treatment-related leukae-
mia [88] and with SMNs occurring among HL survivors
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genetic susceptibility to treatment-related SMNs. A key limi-
tation of previous studies has been a lack of detailed treat-
ment data and/or sufficient sample size to quantify the
effect of specific variants in individuals with differing treat-
ment exposures (e.g. specific radiation dose). Integration of
treatment exposure data to future genetic studies and repli-
cating the findings across different patient populations will
be critical for translating the findings into clinical practice.
Because of the large sample sizes for such studies, interna-
tional collaboration will be essential. Lending further support
to the importance of this research area, several GWAS have
identified genomic regions associated with toxicity after
radiotherapy [90,91]. As such research expands, it will be
important to investigate whether individuals who are suscep-
tible to one treatment-related adverse effect may also be sus-
ceptible to others.
7. Modification of treatment-associated
second cancer risk by lifestyle and
environmental factors
Other cancer risk factors can play an important role in the
development of SMNs. However, only a few studies have
addressed whether these other factors may modify the risk
of treatment-related SMNs, with most studies to date focus-
ing on tobacco use and reproductive factors.
The influence of smoking on the risk of treatment-
associated lung cancer has been examined in several studies
[42,92–95]. In HL survivors, a large international case–control
study examined lung cancer risk in relation to radiation dose,
chemotherapy and smoking [14,42]. The increased RRs from
smoking appeared to multiply the elevated risks from radio-
therapy as well as chemotherapy, with the joint effects of
smoking and treatment significantly stronger than the sum
of the individual effects. Compared with non-smokers who
received less than 5 Gy to the lung area and no alkylating
agents, the largest risk (RR = 49.1) of lung cancer was observed
among moderate-to-heavy smokers given both radiotherapy
and alkylating agents, with a RR of 7.2 for non-smokers given
radiotherapy and chemotherapy (Table 1). It was estimated
that 9.6% of all lung cancers after HL were due to treatment,
24% were due to smoking, and 63% were due to treatment
and smoking in combination [42]. The effect of smoking on
radiation-associated lung cancer risk after breast cancer has
also been examined. Several studies observed that excess
lung cancer risk following post-mastectomy radiotherapy is
restricted to smokers, pointing to strong interaction [93–95].
Several studies have examined the effect of reproductive
factors on the risk of radiation-associated breast cancer. Men-
opausal age has been shown to modify the strongly increased
risk of breast cancer in survivors of HL and childhood cancer
treated with chest radiotherapy [13,25,69,75,96]. In a Dutch
study [25], 30% of female HL survivors reached menopause
before age 41 (related to intensive chemotherapy); such an
early menopause was associated with a 60% (95% CI,
20–80%) reduced risk of RT-associated breast cancer. Women
with less than 10 years of intact ovarian function after radio-
therapy had a 70% (95% CI, 40–80%) decreased risk of breastcancer compared with women with 10–20 years of ovarian
function after irradiation, while those with more than
20 years of intact ovarian function after radiotherapy had
5.3-fold (95% CI, 2.9–9.9) increased risk of breast cancer. These
risk reductions were observed among women treated before
age 31 but not among women treated between ages 31 and
40, possibly because these women were closer to natural
menopause at time of treatment [25]. These results indicate
that ovarian hormones are a crucial factor to promote
tumorigenesis once RT has produced an initiating event. A
recent British study observed stronger radiation-associated
risk of breast cancer among women who were irradiated close
to menarche, suggesting greater carcinogenicity of radiation
when the breast is developing [75]. No modifying effects have
been observed for other risk factors such as age at first birth,
parity and weight, but none of the published studies included
enough women to detect smaller interaction effects or risk
modification by infrequent exposures. Studies had only
limited information on hormone replacement therapy
[25,75,96,97].
Knowledge regarding modifying effects of lifestyle and
reproductive factors on treatment-associated SMN risk is only
beginning to emerge. International collaborative studies are
needed, including large numbers of survivors for whom not
only treatment data are available, but also high-quality data
on lifestyle, reproductive, environmental and occupational
factors. The sequence of treatment exposures and other risk
factors also deserves investigation, particularly for designing
interventions to reduce treatment-related SMN risks where
the treatments interact with modifiable risk factors. Interna-
tional pooling of data already available and data from new
studies are essential to obtain sufficient power for interaction
analyses allowing discrimination between additive, multipli-
cative and supra-multiplicative effects of treatment and other
cancer risk factors.
8. Screening for second malignancy
Given the high relative and absolute risks of several SMNs
identified in cancer survivors (see above), screening to detect
cancers early or to detect pre-malignant lesions ought in prin-
ciple to have considerable potential to reduce the incidence of
and mortality from SMNs. This is dependent, however, on
whether screening can detect cancers early, and whether
early treatment improves prognosis. For many cancers with
increased risks among certain cancer survivors, such as lung
and stomach, no known screening method can affect progno-
sis. By contrast, for breast, cervix and colorectal cancers,
there are well-established screening modalities for the gen-
eral population, giving potential for screening programmes
for cancer patients if they are at increased risk.
Research on screening of cancer survivors has largely
focused on breast cancer after HL and childhood cancer.
National recommendations on screening have been produced
in the United Kingdom (UK) [98] and US [99–101], recommend-
ing that screening starts at a younger age (age 25–30 years, or
8 years after treatment), occurs more frequently (annually)
and involves more modalities (Magnetic Resonance Imaging
(MRI), ultrasound, mammography, alone or in combination)
Table 1 – Risk of lung cancer in patients with Hodgkin lymphoma (HL) according to type of treatment and smoking category.a
Treatment for Hodgkin’s disease RR (95% CI) by smoking category (No. of case patients; control patients)b
Radiation P5 Gy Alkylating agents Non-smoker, light, otherc Moderate-heavyd
No No 1.0e 6.0 (1.9–20.4)
Yes No 7.2 (2.9–21.2) 20.2 (6.8–68)
No Yes 4.3 (1.8–11.7) 16.8 (6.2–53)
Yes Yes 7.2 (2.8–21.6) 49.1 (15.1–187)
a Adapted from Travis et al. (2002) [42].
b Represents estimated tobacco smoking habit 5 years before diagnosis date of lung cancer and corresponding date in control patients, with
the use of information recorded up to 1 year before these dates. RR, relative risk; 95% CI, 95% confidence interval.
c This group includes non-smokers, light current cigarette smokers (less than one pack per day), former cigarette smokers, smokers of cigar
and pipes only and patients for whom tobacco smoking habit was not stated.
d Moderate (one to two packs per day) and heavy (two or more packs per day) current cigarette smokers.
e Reference group.
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gate the value of such programmes, and to improve them, has
been very limited, however, and take-up rates of breast
screening have been found to be rather low [102,103]. Studies
have shown 80–100% of tumours are detectable by mammog-
raphy, and showed a recall rate greater than after general
population screening [102,104–106]. In one study, mammogra-
phy detected mainly Ductal Carcinoma in Situ of the breast
(DCIS), while most invasive cancers were detected between
screenings [106]. Breast cancers diagnosed after HL have been
found more likely to be screen-detected, and more likely to be
diagnosed at an earlier stage, than those in the general popu-
lation [107], and there is some indication that the introduc-
tion of screening may have led to earlier stage diagnosis [108].
With respect to screening modality, it has been shown that
for breast cancers occurring after HL, unlike those in BRCA
mutation carriers, MRI does not have superior sensitivity to
mammography [109,110]. However, mammography and MRI
in combination give substantially greater sensitivity (>90%)
than either alone (67%) [110].
Future research needs to address the age at which screen-
ing should begin, the frequency of screening and the modali-
ties to be used. A specific issue is the benefit, if any, of
screening before age 40, which has not been demonstrated
in the general population or HL patients. Another issue is
how long such patients need intensive screening to continue:
in the UK, they revert at age 50 to the national 3-yearly
screening programme, but their high continuing risk suggests
more-intensive screening may be needed [71]. Most impor-
tantly, there needs to be investigation of whether screening
can decrease mortality in these patients.
Research also needs to investigate whether colorectal can-
cer screening would benefit cancer patients at high risk [20,52]
and the frequency, age at start of screening and modalities that
would have benefit. Currently, in Ontario the take-up of rou-
tine colorectal cancer screening by HL patients has been found
to be only 37% [103]. Research is also needed into whether the
biology of SMNs differs from that of first primaries of the same
site. Cancers induced by radiotherapy, chemotherapy or hor-
monal treatment may have a different pathogenesis, with
potential different susceptibility to screening. For instance,
endometrial cancers after tamoxifen treatment for breast can-
cer are skewed towards non-endometrioid tumours with poorsurvival [111,112], with potential consequences for the success
of screening.
9. Intervention strategies to reduce second
malignancy risk
Developing intervention strategies capable of reducing the
incidence of SMNs is an attractive goal. These might be
employed either during or after treatment for the first cancer
although, of course, post-treatment interventions are the only
options for patients already cured of a first cancer. Interven-
tions may reduce the overall cancer causing potential of treat-
ment by changing its dose or duration, or by focusing it more
accurately on those patients who require it because of unfa-
vourable disease characteristics. Alternatively, an additional
therapeutic intervention may be identified that reduces the
cancer causing potential of the treatment. Lifestyle interven-
tions following treatment are another potentially important
area of investigation.
For HL patients, radiotherapy has been identified as the
main cause of solid SMNs [20]. Therefore, the wide field ‘‘man-
tle’’ [113] and ‘‘inverted Y’’ [114] techniques, the mainstay of
HL treatment in the 1960s and 1970s, were gradually replaced
by much smaller involved field approaches [115]. More
recently ‘‘involved node’’[116] and ‘‘involved site’’ [117] fields
have been developed although clinical trials are required to
evaluate the disease control characteristics and SMN risks
associated with such techniques. ‘‘No radiotherapy’’ strategies
have also been investigated. In a study in early stage HL,
treatment with chemotherapy alone was compared with a
radiotherapy based approach. When first reported this trial
showed inferior disease control in the chemotherapy only
arm [118] but in a subsequent analysis after longer follow-
up, overall survival was superior in these patients due to an
excess of SMNs and other deaths in the radiotherapy arm
[119]. Although criticised for employing outmoded radiother-
apy techniques, this trial raised the possibility of obtaining
a better eventual outcome using chemotherapy alone. It also
highlighted the importance of long follow-up if the full
impact of treatment on survival in terms of both disease con-
trol and late toxicity are to be properly assessed.
More recently, response-adapted approaches whereby
treatment is adjusted according to initial response have been
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Tomography (PET) scan after initial chemotherapy in patients
with early stage HL has identified a population with a very
good prognosis without further treatment. If involved field
radiotherapy is employed following chemotherapy, the 3-year
progression-free survival is marginally better but this is
bought at the expense of irradiating all patients, most of
whom will have already been cured by chemotherapy alone.
This approach to individualisation of treatment will take a
step further if prognostic gene signatures derived from
tumour tissue [121] and capable of identifying low and high
risk patients at diagnosis are integrated with the PET result.
It can be envisaged that minimal therapy would be suitable
for patients with low-risk signatures and a ‘‘negative’’ PET
and more intensive treatment reserved for those with a
high-risk signature and a ‘‘positive’’ PET. Clearly, in these cir-
cumstances, treatment associated with high SMN risk will be
restricted to a section of the population rather than its
entirety.
Additionally, therapeutic risk reduction interventions dur-
ing or following treatment for the first cancer can be consid-
ered for some SMNs. In young women at high risk of breast
cancer as a result of irradiation to breast tissue at a young
age, anti-oestrogens, such as tamoxifen, or interventions to
temporarily delayed onset of menarche may be protective
and studies are currently underway to evaluate the effective-
ness and acceptability of these approaches [122]. As the risk
of breast cancer after chest radiotherapy at young ages is
comparable to that of BRCA mutation carriers [71,123,124],
bilateral prophylactic mastectomy may also be an appropriate
consideration in some patients, especially when they also
have a family history of breast cancer [125].
Lifestyle interventions after treatment may be effective in
reducing the incidence of SMNs and should be evaluated in
appropriately designed clinical trials. These interventions
might include rigorous advice and help to quit smoking,
reduce alcohol consumption, take regular exercise and lose
weight [7,126]. Ideally, trials should incorporate predictive
biomarkers so the value of the intervention can be assessed
long before SMNs emerge, often many years later. Research
should focus on the identification of such biomarkers.10. Conclusions
Over the past decades much knowledge has been gained
about treatment-related risk factors for SMNs. Recently, both
systemic cancer treatments and radiotherapy approaches and
techniques have evolved substantially. It is as yet unclear how
the introduction of these new treatments will influence SMN
risk. For changes in radiotherapy, such as the use of lower
doses and smaller volumes, it may be possible to predict the
associated SMN risk based on computational models for radi-
ation dosimetry established on older regimens [127,128].
However, for completely new agents, drug combinations and
radiation techniques, and interactions between these treat-
ments, large studies with long-term follow-up are needed to
assess SMN risk for at least several decades, in view of the
long induction periods observed for older treatments. In such
studies, high quality treatment data, including radiationdosimetry data (dose–volume information) and cumulative
doses of systemic therapy, are essential. Complete follow-up
of all patients is crucial to avoid selection bias, which can eas-
ily arise if information on SMNs is not derived from linkage
with nationwide cancer registries, but from patient question-
naires or medical records. Several studies have shown that
patients still under surveillance in the original treatment cen-
tre, or participants in questionnaire surveys, may represent
either less healthy or healthier patients [129]. Routine collec-
tion and reporting of SMN data should become an integral
part of randomised controlled trials in oncology.
Currently, very little knowledge is available about factors
that may modify treatment-associated SMN risk, such as
genetic variants and lifestyle or environmental factors.
Although some candidate gene studies in t-AML have shown
interesting results, genome-wide approaches with large sam-
ple sizes are needed to fully explore genetic susceptibility for
treatment-related SMNs. For effective investigation of modi-
fying factors large international collaborative studies with
biobanking are needed to obtain sufficient power for interac-
tion analyses. Such studies should prospectively collect not
only extensive treatment and genetic information, but also
high-quality data on lifestyle, reproductive and other risk fac-
tors. When addressing interaction, it is important to assess
not only interaction at the multiplicative level, but also inves-
tigate whether the joint effects of treatment and a potential
modifier are larger than the sum of the individual effects
(interaction at the additive level), as such interaction may
already impact substantially on the SMN burden of cancer
survivors.
In many countries, recommendations on screening for
SMN (especially breast cancer) have been issued for selected
high-risk survivor groups. However, most guidelines are con-
sensus- rather than evidence-based. Therefore, research is
needed on the diagnostic value of screening tests in this
specific population and the ultimate effect of screening on
mortality. Effective screening is only possible with better
understanding of the pathogenesis of treatment-related
SMNs. Currently, such knowledge is lacking, so there is a
strong need for studies investigating the mechanisms by
which different treatments affect SMN pathogenesis, the clin-
icopathological characteristics of treatment-related SMNs
and their prognosis.
Potentially, the burden of SMNs may also be reduced by
lifestyle or drug interventions. Although smoking cessation
can strongly reduce the risk of treatment-related lung cancer,
no studies with regard to smoking or other interventions have
been conducted. For future patients the most promising way
to reduce SMN risk is through the introduction of new treat-
ments with lesser carcinogenic potential and equivalent cure
rates. Early biomarkers for SMN risk are currently not avail-
able, but would be helpful to use as intermediate end-points
in such trials. Finally, prediction models for SMN risk are
needed to enable more individualised treatment choices
accounting for SMN risk.
While this paper focuses on SMN risk alone, it is important
that late effects research incorporates also other adverse
outcomes and assesses the total burden of adverse health
outcomes in cancer survivors. Such studies could also
investigate whether individuals who are susceptible to
E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 5 –1 7 13treatment-related SMNs, may also be susceptible to other
adverse effects.
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